Fleebs-Logo
Details werden geladen...

US health department proposes testosterone therapy label updates | The Manila Times

The US health department said on Thursday it was seeking updates to labels for testosterone replacement therapies after reviewing new clinical data and other evidence.

Ähnliche Seiten

https://kvia.com/health/cnn-health/2026/06/20/what-men-should-know-about-the-us-governments-latest-move-on-testosterone-therapy/

What men should know about the US government’s latest move on testosterone therapy - KVIA

https://kvia.com/health/cnn-health/2026/06/20/what-men-should-know-about-the-us-governments-latest-move-on-testosterone-therapy/
https://www.manilatimes.net/2026/06/01/tmt-newswire/globenewswire/ascentage-pharma-presents-updated-clinical-data-for-olverembatinib-as-second-line-therapy-in-cml-cp-at-asco-2026/2355278

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 | The Manila Times

https://www.manilatimes.net/2026/06/01/tmt-newswire/globenewswire/ascentage-pharma-presents-updated-clinical-data-for-olverembatinib-as-second-line-therapy-in-cml-cp-at-asco-2026/2355278
https://www.manilatimes.net/2026/06/12/tmt-newswire/globenewswire/novartis-remind-data-at-eaaci-show-rhapsido-potential-as-first-targeted-therapy-for-chronic-inducible-urticaria-cindu/2364302

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) | The Manila Times

https://www.manilatimes.net/2026/06/12/tmt-newswire/globenewswire/novartis-remind-data-at-eaaci-show-rhapsido-potential-as-first-targeted-therapy-for-chronic-inducible-urticaria-cindu/2364302
https://www.manilatimes.net/2026/06/10/tmt-newswire/globenewswire/italfarmaco-announces-health-canada-acceptance-and-priority-review-of-new-drug-submission-for-givinostat-as-a-duchenne-muscular-dystrophy-treatment/2362448

Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment | The Manila Times

https://www.manilatimes.net/2026/06/10/tmt-newswire/globenewswire/italfarmaco-announces-health-canada-acceptance-and-priority-review-of-new-drug-submission-for-givinostat-as-a-duchenne-muscular-dystrophy-treatment/2362448